GemCis

DRUG2 trials

Sponsors

WiSP Wissenschaftlicher Service Pharma GmbH, Centre Hospitalier Universitaire de Saint Etienne

Conditions

Bile Duct CancerUrinary Bladder Cancer

Phase 2

PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer

TerminatedNCT01374789

WiSP Wissenschaftlicher Service Pharma GmbHUrinary Bladder Cancer

Start: 2010-07-31End: 2012-03-31Updated: 2015-06-03

Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours

CompletedNCT02591030

Centre Hospitalier Universitaire de Saint EtienneBile Duct Cancer

Start: 2015-12-15End: 2020-01-16Updated: 2022-02-24

Related Papers

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements

Future Oncology2020-07-17158 citations

Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial.

Journal of Clinical Oncology2019-05-2011 citations